Objective:To investigate the influence of skin allograft rejection on the anti-tumor effects in mice. Methods:BALB/c mice(H-2d genotype) were randomly assigned to 1 of 3 groups named as allograft group grafted with skin from C57BL/6 mice(H-2b genotype), syngeneic graft group grafted with skin from other BALB/c mice, and no graft group, respectively. Each mouse was administered subcutaneously with melanoma cells(B16, H-2b genotype) derived from C57BL/6 mouse, or myeloma cells(SP2/0, H-2d genotype) derived from BALB/c mouse. The graft survival and tumor growth were then followed up. The percentages of spleen CD3+, CD8+T cell and H-2Kb-alloreactive CD8+T cell as well as the infiltration of CD3+T cell in tumor tissue were detected. Results:After B16 cells injection, tumor progressed very fast in both syngeneic graft group and no graft group, but a marked reduction in melanoma growth was found in allograft group followed by a complete tumor regression. After SP2/0 cells administration, rapid tumor progression was found in allograft group, syngeneic graft group and no graft group, with no differences on tumor growth curves. A higher frequency of H-2Kb-alloreactive CD8+T cells was detected in the allograft mice compared with the syngeneic graft mice. Conclusion:Alloskin graft rejection may facilitate the rejection of allogeneic tumor cells, but cannot cross-react with syngeneic tumor cells. |